AzTrials
AzTrials

Procedural PainNCT07916064

Effect of Ketamine on Optic Nerve Sheath Diameter During Procedural Analgesia

An observational study of Procedural Pain and Procedural Sedation and Analgesia, run by Ankara Etlik City Hospital at 1 site in Turkey (Türkiye).

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this observational study is to learn whether ketamine given for procedural analgesia changes intracranial pressure in adult emergency department patients. Intracranial pressure is assessed non-invasively by measuring optic nerve sheath diameter (ONSD) with bedside ultrasonography. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
ketamine
Type of treatment
Injection or infusion
How many people
160 participants
Where
1 siteTurkey (Türkiye)
Study dates
15 Dec 2025to 15 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients (aged 18 years or older) presenting to the Emergency Department of Ankara Etlik City Hospital who receive intravenous ketamine for procedural analgesia as part of routine care.

Who may be able to join

  • Age 18 years or older
  • Hemodynamically stable
  • Receiving intravenous ketamine for procedural analgesia for any clinical indication
  • Written and verbal informed consent

Who cannot join

  • Pregnancy or suspected pregnancy
  • History of moderate or severe head trauma
  • History of cerebrovascular disease
  • Intracranial mass
  • Previous intracranial surgery
  • Signs of increased intracranial pressure
Show all 20Show fewer
  • Chronic obstructive pulmonary disease
  • Hypercapnia
  • Porphyria
  • Liver failure
  • Chronic kidney disease
  • Cerebral palsy
  • Multiple sclerosis
  • Use of antidepressant medication
  • Optic neuritis
  • Globe rupture
  • Glaucoma
  • Use of an agent other than ketamine for procedural analgesia
  • Known allergy or intolerance to ketamine
  • Disorientation, inability to cooperate, or inability to communicate

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Turkey (Türkiye)1 site, 1 recruiting
  • Ankara Etlik City Hospital

    Ankara, Etlik, 06170

    Aylin Topçu Genç, +90 546 581 0996, aylintopcun@gmail.com

    Ömer Faruk Turan, MD, Assoc. Prof.

    Recruiting

Other trials in Turkey (Türkiye)

About this study

Official title: Effect of Ketamine for Procedural Analgesia on Intracranial Pressure: A Prospective Assessment Using Optic Nerve Sheath Diameter

The goal of this observational study is to learn whether ketamine given for procedural analgesia changes intracranial pressure in adult emergency department patients. Intracranial pressure is assessed non-invasively by measuring optic nerve sheath diameter (ONSD) with bedside ultrasonography. The main questions it aims to answer are:

  • Does ONSD change after ketamine administration compared with the measurement taken before ketamine?
  • Does the change in ONSD differ between patients receiving 0.5 mg/kg and 1 mg/kg ketamine? Participants who receive intravenous ketamine as part of their routine emergency care will have ONSD, vital signs, and pain scores recorded before ketamine administration and at 2, 5, 15, and 30 minutes after administration.
Read the detailed description

This prospective observational study is conducted in the Emergency Department of Ankara Etlik City Hospital. Adult patients who receive intravenous ketamine for procedural analgesia are enrolled consecutively after written and verbal informed consent. The decision to use ketamine and the dose (0.5 mg/kg or 1 mg/kg) are made by the treating emergency physician as part of routine care; the study does not assign, change, or interfere with any treatment. Patients are grouped according to the ketamine dose they receive.

Optic nerve sheath diameter (ONSD) is measured with bedside ocular ultrasonography immediately before ketamine administration (minute 0) and at 2, 5, 15, and 30 minutes after administration. Systolic and diastolic blood pressure, heart rate, oxygen saturation, body temperature, and pain intensity (Numeric Rating Scale) are recorded at the same time points. Adverse events related to ketamine are recorded during the 30-minute observation period. Ocular ultrasonography is the only study-specific procedure; it is non-invasive and painless. The planned sample size is 160 patients.

Being tested
ketamine
Keywords
ketamine, optic nerve sheath diameter, ocular ultrasonography, point-of-care ultrasound, emergency department
Medical subject headings
Pain, Procedural, Agnosia, Emergencies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ketamineDrug

    Also called ketalar, Ketamine hydrochloride

    Intravenous ketamine given for procedural analgesia as part of routine emergency care. The dose (0.5 mg/kg or 1 mg/kg) is chosen by the treating physician; the study does not assign or modify treatment.

Study groups in NCT07916064
Study groupRoleWhat they receive
"Ketamine 0.5 mg/kgAdult emergency department patients who receive intravenous ketamine 0.5 mg/kg for procedural analgesia, with the dose chosen by the treating physician as part of routine care.
Receives: Drug: ketamine
Ketamine 1 mg/kgAdult emergency department patients who receive intravenous ketamine 1 mg/kg for procedural analgesia, with the dose chosen by the treating physician as part of routine care.
Receives: Drug: ketamine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Optic Nerve Sheath Diameter From Baseline

    Optic nerve sheath diameter (ONSD, mm) measured by bedside ocular ultrasonography as a non-invasive indicator of intracranial pressure. Change from the pre-ketamine measurement (minute 0) is assessed at each time point after ketamine administration.

    Measured: Before ketamine administration (minute 0) and at 2, 5, 15, and 30 minutes after administration

Secondary outcomes (7)
  1. Change in Optic Nerve Sheath Diameter by Ketamine Dose

    Change in ONSD (mm) from minute 0, compared between patients receiving 0.5 mg/kg and 1 mg/kg ketamine.

    Measured: Before ketamine administration (minute 0) and at 2, 5, 15, and 30 minutes after administration

  2. Change in Systolic Blood Pressure

    Systolic blood pressure (mmHg) measured non-invasively.

    Measured: Before ketamine administration (minute 0) and at 2, 5, 15, and 30 minutes after administration

  3. Change in Diastolic Blood Pressure

    Diastolic blood pressure (mmHg) measured non-invasively.

    Measured: Before ketamine administration (minute 0) and at 2, 5, 15, and 30 minutes after administration

  4. "Change in Heart Rate

    Heart rate (beats per minute).

    Measured: Before ketamine administration (minute 0) and at 2, 5, 15, and 30 minutes after administration

  5. Change in Oxygen Saturation

    Peripheral oxygen saturation (%) measured by pulse oximetry.

    Measured: Before ketamine administration (minute 0) and at 2, 5, 15, and 30 minutes after administration

  6. Change in Pain Intensity

    Pain intensity measured with the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate more severe pain.

    Measured: Before ketamine administration (minute 0) and at 2, 5, 15, and 30 minutes after administration

  7. Number of Participants With Ketamine-Related Adverse Events

    Adverse events attributed to ketamine, observed and recorded by the investigators.

    Measured: From ketamine administration to 30 minutes after administration

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Nov 2026
  2. Study start15 Dec 2025
  3. Primary completion15 Dec 2026 (estimated)
  4. Study completion15 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
160 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07916064
Sponsor's protocol ID
AESH-EK-2025-325
Status last verified
Oct 2026
First submitted
29 Oct 2026
Last updated
4 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared. In accordance with the ethics committee approval, study data are accessible only to the study investigators

Questions about this trial

What is this clinical trial studying?

An observational study of Procedural Pain and Procedural Sedation and Analgesia, run by Ankara Etlik City Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Optic Nerve Sheath Diameter From Baseline (time frame: Before ketamine administration (minute 0) and at 2, 5, 15, and 30 minutes after administration). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in